SCHEMBL2811650

SCHEMBL2811650

Nc1cc(Cl)c(OCc2ccccc2)c(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
GAA P10253 3/20 0.52
MAOB P27338 2/20 0.52
MAPT P10636 2/20 0.52
MAOA P21397 1/20 0.52
RAB9A P51151 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
ALDH1A1 P00352 3/20 0.46
HTT P42858 1/20 0.46
ALOX5AP P20292 1/20 0.46
FEN1 P39748 1/20 0.46
THRB P10828 2/20 0.45
TP53 P04637 1/20 0.45
HTR1A P08908 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29202172 0.85 MRGPRX4 (0.52) KDM4ESMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL7574686 0.84 KDM4E (0.53) KDM4ESMN1; SMN2GAAMAOBMAPT
SCHEMBL8405763 0.83 LMNA (0.50) KDM4ESMN1; SMN2GAAMAPTRAB9A
SCHEMBL257799 0.81 MAPK1 (0.51) KDM4ESMN1; SMN2GAAMAPTL3MBTL1
SCHEMBL27594902 0.81 SMN1; SMN2 (0.46) KDM4ESMN1; SMN2GAAMAPTRAB9A
SCHEMBL25311482 0.81 MAOB (0.51) KDM4ESMN1; SMN2GAAMAOBMAPT
SCHEMBL8806810 0.81 THRB (0.58) KDM4ESMN1; SMN2GAAMAOBMAPT
SCHEMBL20659239 0.81 KDM1A (0.49) KDM4ESMN1; SMN2GAAMAOBMAPT
SCHEMBL6080377 0.81 LMNA (0.47) KDM4ESMN1; SMN2GAAMAOBMAPT
SCHEMBL21295168 0.80 HTR1A (0.61) SMN1; SMN2MAOBMAPTRAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118894802-A Selective THR beta agonist compound and application thereof 山东第一医科大学(山东省医学科学院) 2024-11-05 CN disclosed
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS LTD (GB) 2023-11-09 US disclosed
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS LTD (GB) 2023-11-09 US disclosed
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS LTD (GB) 2023-11-09 US disclosed
EP-4214189-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL Business Ltd (GB) 2023-07-26 EP disclosed
WO-2022058733-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS UCL BUSINESS PLC (GB) 2022-03-24 WO disclosed
US-8236984-B2 Compound and use thereof in the treatment of amyloidosis PENTRAXIN THERAPEUTICS LTD. (GB) 2012-08-07 US disclosed
US-8236984-B2 Compound and use thereof in the treatment of amyloidosis PENTRAXIN THERAPEUTICS LTD. (GB) 2012-08-07 US disclosed
US-20100249233-A1 COMPOUND AND USE THEREOF IN THE TREATMENT OF AMYLOIDOSIS PENTRAXIN THERAPEUTICS LIMITED (GB) 2010-09-30 US disclosed
US-20100249233-A1 COMPOUND AND USE THEREOF IN THE TREATMENT OF AMYLOIDOSIS PENTRAXIN THERAPEUTICS LIMITED (GB) 2010-09-30 US disclosed
US-6262090-B1 Aminopyridine-containing thiourea inhibitors of herpes viruses AMERICAN HOME PRODUCTS CORPORATION 2001-07-17 US disclosed
US-6262082-B1 Diaminopyridine-containing thiourea inhibitors of herpes viruses WYETH 2001-07-17 US disclosed
US-6255349-B1 PREVENTION REPRODUCTION; VIRICIDES AMERICAN HOME PRODUCTS CORPORATION 2001-07-03 US disclosed
US-6207715-B1 USEFUL IN THERAPY OF DISEASES ASSOCIATED WITH HERPES VIRUSES INCLUDING HUMAN CYTOMEGALOVIRUS, HERPES SIMPLEX VIRUSES, EPSTEIN-BARR VIRUS, VARICELLA-ZOSTER VIRUS, HUMAN HERPESVIRUSES-6 AND -7, AND KAPOSI HERPES VIRUS AMERICAN HOME PRODUCTS CORPORATION 2001-03-27 US disclosed
US-6201013-B1 INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) INHIBITOR; SIDE EFFECT REDUCTION, NON-DRUG RESISTANT AMERICAN HOME PRODUCTS CORPORATION 2001-03-13 US disclosed
US-6197803-B1 VIRICIDES; PREVENTION REPRODUCTION AMERICAN HOME PRODUCTS CORPORATION 2001-03-06 US disclosed
US-6166028-A Diaminopuridine-containing thiourea inhibitors of herpes viruses AMERICAN HOME PRODUCTS CORPORATION (US) 2000-12-26 US disclosed
WO-2000034269-A1 THIOUREA INHIBITORS OF HERPES VIRUSES AMERICAN HOME PRODUCTS CORPORATION (US) 2000-06-15 WO disclosed
WO-2000034260-A2 ALPHA-METHYLBENZYL-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING A PHENYLENEDIAMINE GROUP AMERICAN HOME PRODUCTS CORPORATION (US) 2000-06-15 WO disclosed
WO-2000034237-A2 ACETAMIDE AND SUBSTITUTED ACETAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES AMERICAN HOME PRODUCTS CORPORATION (US) 2000-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249233-A1 COMPOUND AND USE THEREOF IN THE TREATMENT OF AMYLOIDOSIS TTR, APP, C1QBP KDM4E 2362/4885SMN1; SMN2 252/4885GAA 397/4885
US-20230357134-A1 AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS TTR, C1R, APOB KDM4E 4178/4885SMN1; SMN2 1033/4885GAA 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.